Table 2.
Clinical Sites of Infection Among the Patient Cohort
| Site of infection | Value |
|---|---|
| Lung | 235 (37.0) |
| Pneumonia | 228 (35.9) |
| Empyema | 7 (1.1) |
| Intra-abdominal | 222 (35.0) |
| Intra-abdominal abscess | 14 (2.2) |
| Ascending cholangitis | 17 (2.7) |
| Cholecystitis | 8 (1.3) |
| Ischemic bowel/bowel infarction | 25 (3.9) |
| Bowel perforation/peritonitis | 23 (3.6) |
| Spontaneous bacterial peritonitis | 112 (17.6) |
| Clostridium difficile enterocolitis/toxic megacolon | 7 (1.1) |
| Others | 16 (2.5) |
| Skin and soft tissue | 29 (4.6) |
| Cellulitis | 6 (0.9) |
| Necrotizing soft tissue infections | 19 (3.0) |
| Others | 4 (0.6) |
| Genitourinary | 41 (6.5) |
| Intravascular catheter infection | 18 (2.8) |
| Primary bloodstream (bacteremia/fungemia without identifiable source) | 50 (7.9) |
| Systemically disseminated (including yeast and tuberculosis) | 22 (3.5) |
| Septic arthritis | 7 (1.1) |
Data are expressed as no. (%). All percentages are out of the total number of patients in the cohort (n = 635). Clinical sites of infection were documented in 548 (86.3%) patients and suspected in 87 (13.7%) patients.